Cerenia

1 x 4 pc

Tablet

Active substance

Maropitant (Maropitant Citrate) : 160 mg

ATC code

QA04AD90 Maropitant

QA04AD Other antiemetics

QA04A Antiemetics and antinauseants

QA04 Antiemetics and antinauseants

QA Alimentary tract and metabolism

Species

Dogs.

Indications

• For the prevention of vomiting induced by motion sickness.

• For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.

Dose to be administered and administration route

For oral use.

For motion sickness, a light meal or snack before dosing is recommended; prolonged fasting before administration should be avoided. However, Cerenia tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of efficacy.

Dogs should be carefully observed following administration to ensure that each tablet is swallowed.

For prevention of vomiting induced by motion sickness, (only for dogs 16 weeks of age or older)

To prevent vomiting induced by motion sickness, Cerenia tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below. Tablets are breakable along the score line on the tablet.

Tablets should be administered at least one hour before starting the journey. The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel. Treatment may be repeated for a maximum of two consecutive days.

Prevention of motion sickness
Dog body weight (kg)	Number of tablets
Dog body weight (kg)	160 mg
7.6–10.0	½
15.1–20.0	1
20.1–30.0	1½
30.1–40.0	2
40.1–60.0	3

As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.

Adverse reactions

Dogs:

Common

(1 to 10 animals / 100 animals treated):

Vomiting¹

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Neurological disorder (e.g. ataxia, convulsion,

seizure, muscle tremor) Lethargy

¹ Observed pre-travel, usually within two hours of dosing.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section “Contact details” of the package leaflet.